These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 24372892)
1. Direct and indirect cost of urge urinary incontinence with and without pharmacotherapy. Goren A; Zou KH; Gupta S; Chen C Int J Clin Pract; 2014 Mar; 68(3):336-48. PubMed ID: 24372892 [TBL] [Abstract][Full Text] [Related]
2. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States. Qin L; Luo X; Zou KH; Snedecor SJ J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196 [TBL] [Abstract][Full Text] [Related]
3. Economic burden of urgency urinary incontinence in the United States: a systematic review. Coyne KS; Wein A; Nicholson S; Kvasz M; Chen CI; Milsom I J Manag Care Pharm; 2014 Feb; 20(2):130-40. PubMed ID: 24456314 [TBL] [Abstract][Full Text] [Related]
4. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881 [TBL] [Abstract][Full Text] [Related]
5. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacoeconomic study of using solifenacin for the treatment of urge urinary incontinence in patients with overactive bladder syndrome]. Avksent'eva MV; Gerasimova KV; Khachatrian GR; Frolov MIu; Omel'ianovskiĭ VV; Avksent'ev NA Urologiia; 2014; (5):56-8, 60-1. PubMed ID: 25807761 [TBL] [Abstract][Full Text] [Related]
7. The effect of hyperactive bladder severity on healthcare utilization and labor productivity. Angulo JC; Brenes FJ; Ochayta D; Lizarraga I; Arumí D; Trillo S; Rejas J Actas Urol Esp; 2014 May; 38(4):249-56. PubMed ID: 24462234 [TBL] [Abstract][Full Text] [Related]
8. Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder. Lee LK; Goren A; Zou KH; Odell K; Russell D; Araiza AL; Luo X Int J Clin Pract; 2016 Jan; 70(1):66-81. PubMed ID: 26662296 [TBL] [Abstract][Full Text] [Related]
9. Impact of overactive bladder on work productivity. Coyne KS; Sexton CC; Thompson CL; Clemens JQ; Chen CI; Bavendam T; Dmochowski R Urology; 2012 Jul; 80(1):97-103. PubMed ID: 22748868 [TBL] [Abstract][Full Text] [Related]
10. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704 [TBL] [Abstract][Full Text] [Related]
12. Tolterodine for the treatment of urge urinary incontinence. Elterman DS; Chughtai B; Kaplan SA; Barkin J Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788 [TBL] [Abstract][Full Text] [Related]
13. The economic impact of overactive bladder syndrome in six Western countries. Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532 [TBL] [Abstract][Full Text] [Related]
14. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Milsom I; Coyne KS; Nicholson S; Kvasz M; Chen CI; Wein AJ Eur Urol; 2014 Jan; 65(1):79-95. PubMed ID: 24007713 [TBL] [Abstract][Full Text] [Related]
15. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275 [TBL] [Abstract][Full Text] [Related]
17. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103 [TBL] [Abstract][Full Text] [Related]
18. The burden of multiple sclerosis in Japan. Nohara C; Hase M; Liebert R; Wu N J Med Econ; 2017 Dec; 20(12):1290-1298. PubMed ID: 28849983 [TBL] [Abstract][Full Text] [Related]
19. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. Staskin DR; Te AE BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722 [TBL] [Abstract][Full Text] [Related]
20. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. Irwin DE; Milsom I; Kopp Z; Abrams P; Cardozo L BJU Int; 2006 Jan; 97(1):96-100. PubMed ID: 16336336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]